Kalaris Therapeutics, Inc. (KLRS): R&D Expense
$30.75M
Year ended 2025-12-31
$32.87M
Trailing 12 months to 2026-06-30
-36.3%
3-year compound annual growth
-9.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.75M | -31.7% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $45.04M | -66.2% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $133.07M | +11.9% | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | $118.87M | -1.5% | 2024-03-15, From 2022-01-01 |
| 2021-12-31 | $120.73M | +143.1% | 2023-02-15, From 2021-01-01 |
| 2020-12-31 | $49.66M | +205.7% | 2022-02-10, From 2020-01-01 |
| 2019-12-31 | $16.25M | n/a | 2021-02-12, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $30.75M | -31.7% |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $104.89M | +11.8% |
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $30.50M | +57.9% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $69.30M | -21.8% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $42.08M | +72.5% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $69.54M | +38.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $10.19M | +12.5% |
Compare KLRS, ABOS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗